MAM
SAVA appoints WATConsult as digital marketing partner for SAVA Herbals
Mumbai: SAVA Healthcare has appointed WATConsult, the hybrid digital agency from the house of dentsu India, as the digital marketing partner for its new herbal formulation business, SAVA Herbals. Through SAVA Herbals, the pharmaceutical company will be launching clinically proven herbal product offerings across various therapy areas.
As per the mandate, WATConsult will oversee social media management, media planning & buying, online reputation management and search engine optimisation for the brand. The key focus of the agency will be to drive the brand growth and complete execution of the strategies across all leading digital and social media platforms generating a high engagement rate and overall connection with the audience, said the statement.
Speaking on the partnership, SAVA Group chairman, Vinod Ramchandra Jadhav said, “SAVA Herbals is an extension of the capabilities that we have built over the years in manufacturing herbal extracts of the highest purity. We truly believe that our association with WATConsult will help us grow and set new benchmarks as we promote our brand’s philosophy of making life feel good.”
SAVA Healthcare head – R&D, Dr Sriram Padmanabhan added, “The products that are being launched by SAVA Herbals have been developed in-house and tested for clinical efficacy and safety in patients, which is very significant. WATConsult will help us spread this message and reach out to customers across.”
Commenting on the association, WATConsult CEO, Heeru Dingra said, “Healthcare is of paramount importance especially in today’s times and so are companies like SAVA that intend to help improve people’s lives. Armed with a lot of new-age thinking and a digital-first approach, we are looking forward to helping the company further scale its efforts and accelerate business growth.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
